Effect of PolyI:C Cotreatment on Halothane-induced Liver Injury in Mice
Overview
Affiliations
Unlabelled: Drug-induced liver injury (DILI) is a challenging problem in drug development and clinical practice. Patient susceptibility to DILI is multifactorial, making these reactions difficult to predict and prevent. Clinical observations have suggested that concurrent bacterial and viral infections represent an important risk factor in determining patient susceptibility to developing adverse drug reactions, although the underlying mechanism is not clear. In the present study, we employed the viral RNA mimetic (polyinosinic-polycytidylic acid [polyI:C]) to emulate viral infection and examined its effect on halothane-induced liver injury. Although pretreatment of mice with polyI:C attenuated halothane hepatotoxicity due to its inhibitory effect on halothane metabolism, posttreatment significantly exacerbated liver injury with hepatocellular apoptosis being significantly higher than that in mice treated with polyI:C alone or halothane alone. The pan-caspase inhibitor z-VAD-fmk suppressed liver injury induced by polyI:C/posthalothane cotreatment, suggesting that the increased hepatocyte apoptosis contributes to the exacerbation of liver injury. Posttreatment with polyI:C also caused activation of hepatic Kupffer cells (KCs) and natural killer (NK) cells and upregulated multiple proapoptotic factors, including tumor necrosis factor-alpha (TNF-alpha), NK receptor group 2, member D (NKG2D), and Fas ligand (FasL). These factors may play important roles in mediating polyI:C-induced hepatocyte apoptosis.
Conclusion: This is the first study to provide evidence that concurrent viral infection can inhibit cytochrome (CYP)450 activities and activate the hepatic innate immune system to proapoptotic factors. DILI may be attenuated or exacerbated by pathogens depending on the time of infection.
Roles of Cofactors in Drug-Induced Liver Injury: Drug Metabolism and Beyond.
Gu R, Liang A, Liao G, To I, Shehu A, Ma X Drug Metab Dispos. 2022; 50(5):646-654.
PMID: 35221288 PMC: 9132098. DOI: 10.1124/dmd.121.000457.
The Immunological Mechanisms and Immune-Based Biomarkers of Drug-Induced Liver Injury.
Liu W, Zeng X, Liu Y, Liu J, Li C, Chen L Front Pharmacol. 2021; 12:723940.
PMID: 34721020 PMC: 8554067. DOI: 10.3389/fphar.2021.723940.
What have we learned from animal models of idiosyncratic, drug-induced liver injury?.
Roth R, Ganey P Expert Opin Drug Metab Toxicol. 2020; 16(6):475-491.
PMID: 32324077 PMC: 7315440. DOI: 10.1080/17425255.2020.1760246.
Beyond Metabolism: Role of the Immune System in Hepatic Toxicity.
Hastings K, Green M, Gao B, Ganey P, Roth R, Burleson G Int J Toxicol. 2020; 39(2):151-164.
PMID: 32174281 PMC: 8297559. DOI: 10.1177/1091581819898399.
Anzaghe M, Resch T, Schaser E, Kronhart S, Diez C, Niles M Front Immunol. 2019; 10:1009.
PMID: 31143178 PMC: 6521796. DOI: 10.3389/fimmu.2019.01009.